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Abstract The present study assessed the impact of early
administration of abciximab in female and male patients
with ST-segment elevation myocardial infarction (STEMI)
transferred for primary angioplasty (PPCI). Data were
gathered for 1,650 consecutive patients with STEMI
transferred for PPCI from hospital networks in seven
countries in Europe from November 2005 to January 2007
(the EUROTRANSFER Registry population). Among
1,086 patients who received abciximab, there were 186
women and 541 men who received abciximab early
([30 min before PPCI), and 86 women and 273 men
treated with late abciximab. Female patients were high-risk
individuals, with advanced age and increased rate of
ischemic events. Early abciximab administration was
associated with enhanced patency of the infarct-related
artery before PPCI, and improved epicardial flow after
PPCI in both women and men. Early abciximab in women
led to the decrease in ischemic events, including 30 day
(adjusted OR 0.26, 95 % CI 0.10–0.69, p = 0.007) and
1 year (adjusted OR 0.37, 95 % CI 0.16–0.84, p = 0.017)
mortality reduction. In contrast, the reduction in 30 day
(adjusted OR 0.69, 95 % CI 0.35–1.39, p = 0.27) and
1 year (adjusted OR 0.68, 95 % CI 0.38–1.22, p = 0.19)
mortality was not significant in men. The frequency of
bleeding events was similar in the early abciximab group
compared to the late abciximab group in both women and
men. Early administration of abciximab improved patency
of the infarct-related artery before and after PPCI, and led
to improved survival in female patients with STEMI.
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The mortality benefit of glycoprotein (GP) IIb–IIIa inhi-
bition during primary percutaneous coronary intervention
(PCI) for ST-segment elevation myocardial infarction
(STEMI) is limited to high-risk patients [1]. An additional
favorable effect in that high-risk group of patients may be
achieved when GPIIb–IIIa inhibitor (abciximab) is given
early, before primary PCI for STEMI [2–6]. Whether the
advantages of upstream abciximab are independent of
gender, an important determinant of outcomes after pri-
mary PCI, has not been reported.
The present study assessed the impact of early admin-
istration of abciximab in female and male patients with
STEMI transferred for primary PCI, based on data from the
European Registry on patients with ST-elevation MI
transferred for mechanical reperfusion with a special focus
on upstream use of abciximab (EUROTRANSFER) [2–4].
Methods
The EUROTRANSFER Registry (http://ClinicalTrials.gov,
number NCT00378391) design and main results have been
previously published [2–4]. In this registry data on 1,650
consecutive patients with STEMI transferred for primary
PCI in 15 STEMI hospital networks from seven European
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countries from November 2005 to January 2007 were
collected. To assess the impact of early administration of
abciximab on clinical outcomes of women and men data on
1,086 patients who received abciximab were retrieved from
the registry database. Patients were stratified based on
gender (women vs men) and abciximab administration
strategy (early vs late administration). Patients who
received abciximab before or during transfer to the PCI-
hospital, at least 30 min before first balloon inflation, or
coronary angiography in patients who did not undergo PCI
were classified as early abciximab patients. The remaining
patients, in whom abciximab was given \30 min to or
during PCI, were analyzed as late abciximab group.
Thrombolysis In Myocardial Infarction (TIMI) risk score
for STEMI was calculated for each patient as described
previously [2, 7]. Patients with C3 points in TIMI risk
score on admission were considered as ‘‘high-risk’’
patients. The study protocol and execution complied with
the declaration of Helsinki and was approved by the
institutional review board.
The primary end point of the present analysis was 1 year
all-cause mortality. In addition, rates of all-cause death,
nonfatal reinfection, urgent revascularization (PCI or cor-
onary artery bypass grafting), puncture site hematoma,
intracranial hemorrhage, and major bleeding requiring
transfusion at 30 days after primary PCI were assessed
[2, 3]. TIMI flow in the infarct-related artery before and
after primary PCI, ST-segment resolution after PCI, and
rate of angiographic PCI complications (no-reflow, distal
embolization) were assessed by visual estimation of local
investigators.
Results were presented as percentages of patients or
medians (interquartile ranges) where applicable. Differ-
ences between groups stratified by gender and abciximab
administration strategy were assessed using Chi-square test
and Fisher’s exact test for dichotomous variables and
Mann–Whitney U test for continuous variables. The effect
of receiving early abciximab versus late abciximab on
clinical outcome parameters was presented as odds ratio
and 95 % confidence interval. To adjust for possible
selection bias, propensity score [8] for the likelihood of
receiving abciximab early was calculated based on the
following variables: sex, age, body mass index, medical
history (previous myocardial infarction, chronic kidney
disease, previous heart failure symptoms, previous PCI,
previous coronary artery bypass grafting, previous stroke,
smoking status, diabetes mellitus, peripheral arterial dis-
ease), medications before admission (clopidogrel and
thrombolysis before PCI-hospital), time from chest pain
onset to diagnosis, diagnosis to balloon time and the
location where the STEMI diagnosis was made (ambulance
or referral hospital). Differences in clinical outcomes
between patients treated with early abciximab versus late
abciximab were adjusted for propensity score using logistic
regression analysis and presented as adjusted odds ratio
with 95 % confidence interval. Difference in death rates
between groups during follow-up was assessed by the
Kaplan–Meier method using log-rank test. All tests were
2-tailed and a p value \0.05 was considered statistically
significant. All analyses were performed with SPSS 15.0
(SPSS Inc., Chicago, Illinois).
Results
Data on 1,650 patients were entered into the EURO-
TRANSFER Registry. Overall, 1,086 patients, including
272 women (25 %) and 814 men receiving abciximab were
identified (study group). Among women 186 patients
(68.4 %) were classified as early abciximab patients, and
86 as late abciximab patients. Similarly, among men 541
patients (66.5 %) were classified as early abciximab
patients, and 273 as late abciximab patients (p = 0.56).
Women were older (women vs men, median age: 70.5
(62–79) vs 62 (52–71) years, p \ 0.0001), with a
higher prevalence of diabetes mellitus (19.5 vs 14.1 %,
p = 0.034), and have experienced longer delays from
symptom onset to PCI (median time: 226 (160–335) vs 206
(143–321) min, p = 0.19) than men. In addition, the per-
centage of patients classified as ‘‘high-risk’’ (TIMI risk
score C3 points) was higher in women than men (74.3 vs
50.9 %, p \ 0.001). Clinical, angiographic and procedural
characteristics of the study patients according to gender
and abciximab administration strategy are shown in
Table 1. Baseline characteristics were similar in the early
abciximab group compared to the late abciximab group in
both women and men, except more advanced age and less
frequent chronic kidney disease presence in male patients
receiving abciximab early than late. As shown in Table 1,
women receiving abciximab late were more likely to be
treated with drug-eluting stents during primary PCI than
women receiving abciximab early. Femoral access site and
thrombus aspiration catheters were less frequently used in
male patients receiving abciximab early than late.
Despite no difference in frequency of initial TIMI grade
2–3 flow between women and men (women vs men: 28.3
vs 27.9 %, p = 0.89), the rates for final TIMI grade 3 flow
after PCI (85.9 vs 93.0 %, p \ 0.001) were lower in female
patients. In addition, women were at higher risk of
no-reflow (5.9 vs 2.8 %, p = 0.024) and distal emboliza-
tion (3.9 vs 1.7 %, p = 0.036) during primary PCI. How-
ever, the rates for ST-segment resolution [50 % assessed
60 min after PCI were similar in both groups (73.5 vs
75.4 %, p = 0.53). Early administration of abciximab
before primary PCI was associated with enhanced patency
of the infarct-related artery before PCI, and improved
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epicardial flow, as well as ST-segment resolution after PCI
(Fig. 1) in both women and men. In contrary, benefits of
early use of abciximab in terms of the reduction in
angiographic complications of PCI were limited to female
patients.
Higher rates for all bleeding events (women vs men:
15.1 vs 7.7 %, p \ 0.001), as well as 30 day (7.7 vs
4.3 %, p = 0.027) and 1 year (10.7 vs 6.1 %, p = 0.013)
death were observed in female patients. Strategy of early
initiation of abciximab in women led to significant
decrease in ischemic events including 30 day and 1 year
mortality reduction. Importantly, observed difference
was significant after adjustment for potential confound-
ers (Table 2). In contrary, among men only a trend
towards improved 1 year survival related to early treat-
ment with abciximab was confirmed. The frequency of
bleeding events in the early abciximab group was similar
to that observed in the late abciximab group in both
women and men (Table 2). As shown in the Fig. 2, the
1 year survival among women receiving early abciximab
was as good as for men receiving abciximab either early
or late.
Table 1 Clinical, angiographic and procedural characteristics of women and men stratified by abciximab administration strategy
Variable Women (n = 272) p value Men (n = 814) p value
Early abciximab
(n = 186)
Late abciximab
(n = 86)
Early abciximab
(n = 541)
Late abciximab
(n = 273)
Age (years) 69 (60–78) 73 (65–79) 0.15 63 (52–71) 60 (51–71) 0.038
Age C75 years 39.2 % 43.0 % 0.60 16.1 % 12.8 % 0.25
Body mass index (kg/m2) 26.6 (24.0–29.4) 26.3 (23.2–31.1) 0.59 26.8 (24.3–29.3) 26.8 (24.4–29.7) 0.64
Previous myocardial infarction 8.6 % 11.6 % 0.51 10.9 % 13.6 % 0.30
Previous heart failure symptoms 0.5 % 2.3 % 0.24 0.9 % 0.7 % 0.99
Previous percutaneous coronary intervention 7.0 % 11.6 % 0.20 7.6 % 9.5 % 0.35
Previous coronary artery bypass grafting 0.5 % 2.3 % 0.24 1.1 % 2.2 % 0.23
Current smoker 25.3 % 29.1 % 0.55 38.6 % 40.3 % 0.65
Diabetes mellitus 21.0 % 16.3 % 0.41 13.5 % 15.4 % 0.52
Insulin 9.1 % 5.8 % 0.48 3.7 % 4.0 % 0.85
Peripheral arterial disease 2.7 % 3.5 % 0.71 2.4 % 2.9 % 0.82
Previous stroke 4.3 % 2.3 % 0.51 3.5 % 2.9 % 0.69
Chronic kidney disease 2.2 % 2.3 % 0.99 1.5 % 4.0 % 0.028
Time from symptoms onset to diagnosis (min) 110 (65–200) 121 (61–235) 0.64 85 (50–180) 100 (60–196) 0.13
Aspirin before cathlab 94.6 % 88.4 % 0.08 95.9 % 92.7 % 0.06
Clopidogrel before cathlab 21.5 % 25.6 % 0.53 21.4 % 26.7 % 0.10
Unfractionated heparin before cathlab 77.4 % 69.8 % 0.23 69.7 % 68.5 % 0.75
Heart rate on admission (beats per min) 74 (65–88) 80 (66–90) 0.32 75 (66–86) 80 (68–90) 0.06
Systolic blood pressure on admission (mmHg) 130 (110–150) 138 (110–160) 0.45 130 (117–150) 134 (114–149) 0.55
Diastolic blood pressure on admission (mmHg) 76 (65–90) 80 (66–90) 0.67 80 (70–90) 80 (70–90) 0.08
Killip class IV on admission 2.7 % 3.5 % 0.71 2.6 % 4.0 % 0.29
TIMI risk score C3 points 71.5 % 80.2 % 0.14 51.8 % 49.1 % 0.50
Femoral access 83.3 % 90.7 % 0.14 81.5 % 89.0 % 0.006
LAD as infarct-related artery 44.6 % 43.0 % 0.90 48.4 % 45.4 % 0.46
Multivessel disease 49.7 % 52.3 % 0.70 49.2 % 51.5 % 0.55
Intra-aortic balloon pumping 3.2 % 4.7 % 0.73 3.9 % 4.4 % 0.85
Immediate PCI n = 175 n = 80 n = 516 n = 256
Time from symptoms onset to PCI (min) 223 (165–329) 237 (145–359) 0.98 201 (140–309) 213 (153–340) 0.15
Stents 86.3 % 87.5 % 0.85 94.2 % 96.9 % 0.11
Drug-eluting stent 24.5 % 38.6 % 0.038 33.5 % 35.5 % 0.62
Direct stenting 15.2 % 17.1 % 0.84 18.1 % 19.8 % 0.62
Thrombus aspiration 10.3 % 11.2 % 0.83 9.7 % 19.5 % \0.001
Non-infarct-related artery PCI 4.6 % 5.0 % 0.99 5.6 % 4.7 % 0.62
Values are presented as percentages or medians (interquartile ranges)
LAD left anterior descending artery, PCI percutaneous coronary intervention, TIMI thrombolysis in myocardial infarction
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Discussion
The main finding of the present study is that among women
with STEMI, the early use of abciximab enhances myo-
cardial reperfusion before and after primary PCI, and leads
to improved survival.
Women presenting with STEMI are high-risk individu-
als, with advanced age, and higher prevalence of comor-
bidities than man [9–11]. In addition, successful
reperfusion in women is frequently delayed due to an
atypical presentation. Contrary to reports from De Luca
et al. [10, 11] and Lansky et al. [9] suggesting no impact of
gender on reperfusion success, in our study female patients
were less likely to achieve TIMI grade 3 flow and more
likely to have angiographic complications after primary
PCI than did men. Importantly, female patients with
STEMI treated with primary PCI had higher unadjusted
30 day and 1 year mortality. However, that difference in
mortality between women and men is related rather to the
difference in their risk profile, and female sex did not
emerge as an independent predictor of death [9–11]. The
observed difference in bleeding was driven principally by
the higher rate of puncture site hematomas in female
patients. Interestingly, female gender carries an increased
risk of local hematomas even in patients treated through the
radial approach during primary PCI [12].
GPIIb–IIIa inhibition during primary PCI improves
myocardial perfusion and long-term survival [13].
However, in a meta-regression analysis from De Luca et al.
[1], the mortality benefit of GPIIb–IIIa inhibitors during
primary PCI for STEMI was limited to high-risk patients.
Data assessing the impact of gender on the safety and
efficacy of GPIIb–IIIa inhibitors during primary PCI are
limited. Pooled analysis from EPIC, EPILOG and EPIS-
TENT trials demonstrated no gender difference in protec-
tion from major adverse outcomes with GPIIb–IIIa
inhibition with abciximab during planned or urgent PCI
[14]. Although women had higher rates for both major and
minor bleeding events with abciximab compared with men.
In contrary, in the ISAR-REACT 2 study higher effec-
tiveness of abciximab used on top of 600 mg clopidogrel
loading-dose among men than women was confirmed in
patients with non-ST-elevation acute coronary syndrome
undergoing PCI [15]. On the other hand, in the CADIL-
LAC study the addition of abciximab during primary PCI
for STEMI in female patients significantly reduced 30 day
target-vessel revascularization without increasing bleeding
risk, especially when women were treated with stent [9].
As confirmed by HORIZONS-AMI study, replacement of
combination of unfractionated heparin and GPIIb–IIIa
inhibitor with bivalirudin during primary PCI may reduce
the rates of major bleeding and net adverse clinical events
during 30 day follow-up, and both of these effects are
independent of gender [16].
Additional clinical benefit may be achieved in patients
with STEMI when GPIIb–IIIa inhibitor (abciximab) is
Fig. 1 Angiographic and
electrocardiographic
characteristics of women
(a) and men (b) stratified by
abciximab administration
strategy (early abciximab-empty
bars late abciximab solid bars).
PCI percutaneous coronary
intervention, STR ST-segment
resolution, TIMI thrombolysis in
myocardial infarction
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given upstream, before primary PCI [2–6]. However,
present analysis confirmed that mortality benefit of early
abciximab administration may be limited to patients with a
higher baseline risk profile, including female patients. This
finding is in line with our previous reports showing that
early administration of abciximab before transportation for
primary PCI is associated with significantly lower 1 year
mortality in high-risk patients (TIMI risk score C3), dia-
betic, and elderly patients (C65 years of age) [2, 3, 17].
Importantly, upstream use of abciximab was not associated
with excessive bleeding risk, including no increase in
major bleeding requiring transfusion in comparison to
administration during PCI in both women and men. Simi-
larly to our results, in the EGYPT cooperation analysis on
patients with STEMI early administration of GPIIb–IIIa
inhibitors enhanced patency of the infarct-related artery
before and after primary PCI and led to mortality reduction
(for patients treated with abciximab) [5]. No interaction
between gender and effects of upstream GPIIb–IIIa
inhibitors administration on mortality was confirmed. In
the recently published MISTRAL study, despite enhance-
ment of early reperfusion before PCI, and reduction of the
risk of angiographic complications of PCI no mortality
benefit was confirmed for in the ambulance versus in the
cathlab use of abciximab [18]. Importantly, the MISTRAL
study included rather small and highly selected population
with a low-risk profile (Killip class [I in 8 % of patients,
diabetes mellitus in 8 %, and overall mortality 1.17 %).
Results achieved by women and men in this study have not
yet been reported. In the On-TIME-2 study prehospital
initiation of another GPIIb–IIIa inhibitor (high-bolus dose
of tirofiban) improved ST-segment resolution and clinical
outcome after primary PCI, however no difference in
mortality between study groups was observed [19].
Importantly, the benefits of tirofiban in terms of reduction
of primary efficacy endpoint (the extent of residual
ST-segment deviation at 1 h after PCI) were more pro-
nounced in women than men.
Table 2 Clinical outcomes of women and men stratified by abciximab administration strategy
Variable Early
abciximab
Late
abciximab
OR (95 % CI) p value Adjusted
OR (95 % CI)
p value
Women n = 186 n = 86
30 day
Death 4.8 % 14.0 % 0.31 (0.13–0.78) 0.023 0.26 (0.10–0.69) 0.007
Death ? nonfatal reinfarction 6.5 % 16.3 % 0.36 (0.16–0.80) 0.013 0.29 (0.12–0.69) 0.005
Death ? nonfatal reinfarction
? urgent revascularization
7.5 % 17.4 % 0.39 (0.18–0.84) 0.016 0.32 (0.14–0.74) 0.007
Major bleeding requiring transfusion 5.4 % 2.3 % 2.39 (0.51–11.13) 0.27 2.22 (0.47–10.57) 0.32
Intracranial haemorrhage 0 % 0 % – – – –
Puncture site haematoma 12.9 % 9.3 % 1.44 (0.62–3.36) 0.39 1.21 (0.51–2.88) 0.67
All bleeding 16.7 % 11.6 % 1.52 (0.71–3.26) 0.28 1.30 (0.60–2.85) 0.51
1 year
Death 7.5 % 17.4 % 0.39 (0.18–0.84) 0.016 0.37 (0.16–0.84) 0.017
Men n = 541 n = 273
30 day
Death 3.7 % 5.5 % 0.66 (0.33–1.31) 0.24 0.69 (0.35–1.39) 0.27
Death ? nonfatal reinfarction 4.6 % 7.0 % 0.65 (0.35–1.20) 0.17 0.68 (0.37–1.28) 0.23
Death ? nonfatal reinfarction
? urgent revascularization
5.0 % 8.1 % 0.60 (0.34–1.07) 0.09 0.64 (0.36–1.17) 0.15
Major bleeding requiring transfusion 1.3 % 1.1 % 1.18 (0.30–4.60) 0.81 1.40 (0.35–5.64) 0.64
Intracranial haemorrhage 0 % 0 % – – – –
Puncture site haematoma 6.7 % 7.3 % 0.90 (0.51–1.59) 0.72 0.94 (0.53–1.68) 0.83
All bleeding 7.6 % 8.1 % 0.94 (0.55–1.61) 0.81 0.98 (0.57–1.71) 0.95
1 year
Death 5.2 % 8.1 % 0.62 (0.35–1.11) 0.11 0.68 (0.38–1.22) 0.19
Values are presented as percentages and unadjusted and adjusted for propensity score odds ratios (OR) with 95 % confidence intervals (CI)
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In our registry, abciximab was given intravenously.
There is growing interest in the intracoronary [20] or int-
ralesion [21] administration of abciximab via dedicated
therapeutic perfusion catheter. Local administration of
abciximab increases concentrations at the culprit lesion and
in the distal vascular bed, and allows to improve the dif-
fusion of abciximab to platelets within flow-limiting
thrombi. By potentiating the local anti-inflammatory
effects of abciximab, reperfusion injury may be minimized
resulting in greater myocardial salvage. However, no
clinical benefit of intracoronary versus intravenous
administration of abciximab through the guiding catheter
during primary PCI was confirmed in the large, randomized
study [20]. In the recently reported INFUSE AMI trial local
administration of abciximab was associated with signifi-
cant, however, modest reduction of the infarct size assessed
by cardiac magnetic resonance at 30 days after first, ante-
rior wall STEMI in comparison to no abciximab adminis-
tration [21]. No data comparing early administration of
abciximab vs intracoronary administration are available.
New P2Y12 inhibitors–prasugrel [22] and ticagrelor
[23] may overcome limitations of clopidogrel in patients
with STEMI, as both have shown more potent antiplatelet
effect and a higher clinical benefit. Present study suggests
that early abciximab administration is still a reasonable
strategy for high-risk patients with STEMI, including
women when the bleeding risk profile is acceptable, how-
ever the relevance of that treatment strategy on top of new
oral antiplatelet agents, especially given in a prehospital
setting requires further studies.
Limitations
Several important limitations need to be kept in mind when
interpreting the results of this study. The main limitation is
the non-randomized nature of the study and the potential of
selection bias. Even using propensity score adjustment, we
were unable to control all patients, operator and center-
related factors influencing an association between early
abciximab use and patient outcome. Interpretation of TIMI
flow, no-reflow, distal embolization, and ST-segment res-
olution were limited by the fact that these represent not an
independent core laboratory but physicians assessments.
Unfortunately, important data on either thrombus grading
or myocardial perfusion grading were not available.
However, these limitations might not influence the results
of the study, as both groups were exposed to confounding
factors and were relatively large.
Conclusions
Early administration of abciximab improved patency of the
infarct-related artery before and after PPCI, and led to
improved survival in female patients with STEMI.
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